Arben Ventures was founded by Stanford researchers, including Ariel Ganz, whose work in precision mental health, multi-omics, and personal experience with early disease detection shape the fund's focus on backing overlooked founders at the earliest stage of deep-tech health, from precision medicine and longevity to specific clinical problems like diabetic foot ulcer detection and AI for biologics manufacturing. Known as one of the most active pre-seed investors in this niche, with 63 startup investments in about 24 months, the fund includes Peter Gray, emeritus partner at Wellcome Trust, as a venture partner, reflecting a team with deep ties to scientific research rather than a traditional finance background.